The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis

Reproduction

Volumn 142, Issue 5, 2011, Pages 745-755

  Delgado Rosas, Francisco ^a   Goḿez, Rauĺ ^a   Ferrero, Hortensia ^a   Gaytan, Francisco ^b   Garcia Velasco, Juan ^a   Simoń, Carlos ^a   Pellicer, Antonio ^a  

^a Biomedical Research Institute Hospital Clinic de Valencia INCLIVA   (Spain)

^b Facultad de Medicina de Córdoba   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; QUINAGOLIDE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOMETRIOSIS; FEMALE; GENE EXPRESSION PROFILING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; BLOOD VESSELS; CELL COUNT; CELL PROLIFERATION; CLAVICEPS; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; ENDOMETRIOSIS; ENDOMETRIUM; ERGOLINES; FEMALE; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, DOPAMINE D2; UTERINE DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS MUSCULUS;

EID: 80355138179     PISSN: 14701626     EISSN: 17417899     Source Type: Journal    
DOI: 10.1530/REP-11-0223     Document Type: Article

References (53)

1. Álvarez González ML, Galant C, Frankenne F, Nisolle M, Labied S, Foidart JM, Marbaix E & Béliard A 2009 Development of an animal experimental model to study the effects of levonorgestrel on the human endometrium. Human Reproduction 24 697-704. (doi:10.1093/humrep/den437)
2. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA & Bliss VS 2001 The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nature Medicine 7 569-574. (doi:10.1038/87895)
3. Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS & Mukhopadhyay D 2004 Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Research 64 5551-5555. (doi:10.1158/0008-5472.CAN-04-1600)
4. Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA, Short SM, Taylor GA, Folkman J & D'Amato RJ 2005 Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertility and Sterility 84 1144-1155. (doi:10.1016/j.fertnstert.2005.04.040)
5. Belur LR, Podetz-Pedersen KM, Sorenson BS, Hsu AH, Parker JB, Carlson CS, Saltzman DA, Ramakrishnan S & McIvor RS 2011 Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System. Molecular Cancer 10 14. (doi:10.1186/1476-4598-10-14)
6. Benjamin LE, Hemo I & Keshet E 1998 A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125 1591-1598. (Pubitemid 28256727)
7. Bourlev V, Volkov N, Pavlovitch S, Lets N, Larsson A & Olovsson M 2006 The relationship between microvessel density, proliferative activity and expression of vascular endothelial growth factor-A and its receptors in eutopic endometrium and endometriotic lesions. Reproduction 132 501-509. (doi:10.1530/rep.1.01110)
8. Bruner-Tran KL, Webster-Clair D & Osteen KG 2002 Experimental endometriosis: the nude mouse as a xenographic host. Annals of the New York Academy of Sciences 955 328-339. (doi:10.1111/j.1749-6632.2002.tb02793.x)
9. Caulet S, Lesty C, Raphael M, Schoevaert D, Brousset P, Binet JL, Diebold J & Delsol G 1992 Comparative quantitative study of Ki-67 antibody staining in 78 B and T cell malignant lymphoma (ML) using two image analyser systems. Pathology, Research and Practice 188 490-496.
10. Chakroborty D, Chowdhury UR, Sarkar C, Baral R, Dasgupta PS & Basu S 2008 Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. Journal of Clinical Investigation 118 1380-1389. (doi:10.1172/JCI33125)
11. Colao A, di Sarno A, Pivonello R, di Somma C & Lombardi G 2002 Dopamine receptor agonists for treating prolactinomas. Expert Opinion on Investigational Drugs 11 787-800. (doi:10.1517/13543784.11.6.787)
12. Cristina C, Díaz-Torga G, Baldi A, Góngora A, Rubinstein M, Low MJ & Becú Villalobos D 2005 Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice. Endocrinology 146 2952-2962. (doi:10.1210/en.2004-1445)
13. Cunha-Filho JS, Gross JL, Lemos NA, Dias EC, Vettori D, Souza CA & Passos EP 2002 Prolactin and growth hormone secretion alter thyrotrophin- releasing hormona infusion and dopaminergic (DA2) blockade in infertile patients with minimal/mild endometriosis. Human Reproduction 17 960-965. (doi:10.1093/humrep/17.4.960)
14. Donnez J, Smoes P, Gillerot S, Casanas-Roux F & Nisolle M 1998 Vascular endothelial growth factor in endometriosis. Human Reproduction 13 1686-1690. (doi:10.1093/humrep/13.6.1686)
15. Eggermont J, Donnez J, Casanas-Roux F, Scholtes H & Van Langendonckt A 2005 Time course of pelvic endometriotic lesion revascularization in a nude mouse model. Fertility and Sterility 84 492-499. (doi:10.1016/j.fertnstert.2005. 03.034)
16. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH et al. 2008 VEGF inhibition and renal thrombotic microangiopathy. New England Journal of Medicine 358 1129-1136. (doi:10.1056/NEJMoa0707330)
17. Ferrero H, Gaytán F, Delgado-Rosas F, Gaytán M, Gómez R, Simón C & Pellicer A 2010 Dopamine receptor 2 (drd2) activation inhibits VEGF secretion in granulosa luteinized cells: implications for OHSS treatment in low drd2 milieus. Human Reproduction 25 (Supplement 1) i56-i58. (doi:10.1093/humrep/de.25.s1.40)
18. Galle PC 1989 Clinical presentation and diagnosis of endometriosis. Obstetrics and Gynecology Clinics of North America 16 29-42. (Pubitemid 19054702)
19. Gómez R, González-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, Remohi J, Simon C & Pellicer A 2006 Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 147 5400-5411. (doi:10.1210/en.2006-0657)
20. Gregoriou O, Konidaris S, Vitoratos N, Papadias C, Papoulias I & Chryssicopoulos A 1997 Gonadotropin releasing hormone analogue plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. International Journal of Fertility and Women's Medicine 42 406-411.
21. Gregoriou G, Bakas P, Vitoratos N, Papadias K, Goumas K, Chryssicopoulos A & Creatsas G 1999 Evaluation of serum prolactin levels in patients with endometriosis and infertility. Gynecologic and Obstetric Investigation 48 48-51. (doi:10.1159/000010133)
22. Grümmer R 2006 Animals models in endometriosis research. Human Reproduction Update 5 641-649. (doi:10.1093/humupd/dml026)
23. Guo Y, He B, Xu X & Wang J 2011 Comprehensive analysis of leukocytes, vascularization and matrix metalloproteinases in human menstrual xenograft model. PLoS ONE 6 e16840. (doi:10.1371/journal.pone.0016840)
24. Heryanto B, Lipson KE & Rogers PA 2003 Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse. Reproduction 125 337-346. (doi:10.1530/rep.0.1250337)
25. Hull ML, Charnock-Jones DS, Chan CLK, Bruner-Tran KL, Osteen KG, Tom BD, Fan TP & Smith SK 2003 Antiangiogenic agents are effective inhibitors of endometriosis. Journal of Clinical Endocrinology and Metabolism 88 2889-2899. (doi:10.1210/jc.2002-021912)
26. Hull ML, Escareno CR, Godsland JM, Doig JR, Johnson CM, Phillips SC, Smith SK, Tavaré S, Print CG & Charnock-Jones DS 2008 Endometrial-peritoneal interactions during endometriotic lesion establishment. American Journal of Pathology 173 700-715. (doi:10.2353/ajpath.2008.071128)
27. Machado DE, Abrão MS, Berardo PT, Takiya CM & Nasciutti LE: 2008 Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertility and Sterility 90 148-155. (doi:10.1016/j.fertnstert.2007.05.076)
28. Machado DE, Berardo PT, Palmero CY & Nasciutti LE 2010 Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases. Journal of Experimental & Clinical Cancer Research 29 4. (doi:10.1186/1756-9966-29-4)
29. Masuda H, Maruyama T, Hiratsu E, Yamane J, Iwanami A, Nagashima T, Ono M, Miyoshi H, Okano HJ, Ito M et al. 2007 Noninvasive and real-time assessment of reconstructed functional human endometrium in NOD/SCID/gamma c (null) immunodeficient mice. PNAS 104 1925-1930. (doi:10.1073/pnas.0604310104)
30. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D & Moots RJ 2002 Dopamine receptor expression on human Tand B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. Journal of Neuroimmunology 132 34-40. (doi:10.1016/S0165- 5728(02)00280-1)
31. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Müller KH, Sharkey AM & Smith SK 1996 Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. Journal of Clinical Investigation 98 482-489. (doi:10.1172/JCI118815)
32. Meduri G, Bausero P & Perrot-Applanat M 2000 Expression of vascular endothelial growth factor receptors in the human endometrium: modulation during the menstrual cycle. Biology of Reproduction 62 439-447. (doi:10.1095/ biolreprod62.2.439)
33. Moody DM, Thore CR, Anstrom JA, Challa VR, Langefeld CD & Brown WR 2004 Quantification of afferent vessels shows reduced brain vascular density in subjects with leukoaraiosis. Radiology 233 883-890. (doi:10.1148/radiol. 2333020981)
34. Nap AW, Griffioen AW, Dunselman GA, Bouma-TerSteege JC, Thijssen VL, Evers JL & Groothuis PG 2004 Antiangiogenesis therapy for endometriosis. Journal of Clinical Endocrinology and Metabolism 89 1089-1095. (doi:10.1210/jc.2003-031406)
35. Nisolle M, Casanas-Roux F, Anaf V, Mine JM & Donnez J 1993 Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertility and Sterility 59 681-684. (Pubitemid 23086336)
36. Novella-Maestre E, Carda C, Noguera I, Ruiz-Saurí A, Garcia-Velasco JA, Simon C & Pellicer A 2009 Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Human Reproduction 24 1025-1035. (doi:10.1093/humrep/den499)
37. Pauli SA, Tang H, Wang J, Bohlen P, Posser R, Hartman T, Sauer MV, Kitajewski J & Zimmermann RC 2005 The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 146 1301-1311. (doi:10.1210/en.2004-0765)
38. Punyadeera C, Thijssen VL, Tchaikovski S, Kamps R, Delvoux B, Dunselman GA, de Goeij AF, Griffioen AW & Groothuis PG 2006 Expression and regulation of vascular endothelial growth factor ligands and receptors during menstruation and post-menstrual repair of human endometrium. Molecular Human Reproduction 12 367-375. (doi:10.1093/molehr/gal027)
39. Reese J, Binart N, Brown N, Ma WG, Paria BC, Das SK, Kelly PA & Dey SK 2000 Implantation and decidualization defects in prolactin receptor (PRLR)-deficient mice are mediated by ovarian but not uterine PRLR. Endocrinology 141 1872-1881. (doi:10.1210/en.141.5.1872)
40. Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, Rocchi F, Gangi E, Paracchi S, Gasperi M et al. 2002 Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reproductive Toxicology 16 791-793. (doi:10.1016/S0890-6238(02)00055-2)
41. Robert E, Musatti L, Piscitelli G & Ferrari CI 1996 Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reproductive Toxicology 10 333-337. (doi:10.1016/0890-6238(96)00063-9)
42. Rockwell LC, Pillai S, Olson CE & Koos RD 2002 Inhibition of vascular endothelial growth factor/vascular permeability factor action blocks estrogen induced uterine edema and implantation in rodents. Biology of Reproduction 67 1804-1810. (doi:10.1095/biolreprod.102.006700)
43. Roth BL 2007 Drugs and valvular heart disease. New England Journal of Medicine 356 6-7. (doi:10.1056/NEJMp068265)
44. Schade R, Andershon S, Suissa S, Haverkamp W & Garbe E 2007 Dopamine agonists and the risk of cardiac-valve regurgitation. New England Journal of Medicine 356 29-38. (doi:10.1056/NEJMoa062222)
45. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N, Jaffe RB & Taylor RN 1996 Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. Journal of Clinical Endocrinology and Metabolism 81 3112-3118. (doi:10.1210/jc.81.8.3112)
46. Verhelst J, Abs R, Maiter D, Van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P et al. 1999 Cabergoline in the treatment of hyperprolactinemia: a study of 455 patients. Journal of Clinical Endocrinology and Metabolism 84 2518-2522. (doi:10.1210/jc.84.7.2518)
47. Walch K, Unfried G, Huber J, Kurz C, van Trotsenburg M & Pernicka E 2009 Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis - a pilot study. Contraception 79 29-34. (doi:10.1016/j.contraception.2008.07.017)
48. Wang D, Stockard CR, Harkins L, Lott P, Salih C, Yuan K, Buchsbaum D, Hashim A, Zayzafoon M, Hardy RWet al. 2008 Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotechnic & Histochemistry 83 179-189. (doi:10.1080/10520290802451085)
49. Wulff C, Wilson H, Rudge JS, Wiegand SJ, Lunn SF & Fraser HM 2001 Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap (A40). Journal of Clinical Endocrinology and Metabolism 86 3377-3386. (doi:10.1210/jc.86.7.3377)
50. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S & Pezzoli G 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease. New England Journal of Medicine 356 39-46. (doi:10.1056/NEJMoa054830)
51. Zimmermann RC, Hartman T, Bohlen P, Sauer MV & Kitajewski J 2001a Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvascular Research 62 15-25. (doi:10.1006/mvre.2001.2312)
52. Zimmermann RC, Xiao E, Husami N, Sauer MV, Lobo R, Kitajewski J & Ferin M 2001b Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. Journal of Clinical Endocrinology and Metabolism 86 768-772. (doi:10.1210/jc.86.2.768)
53. Zimmermann RC, Hartman T, Kavic S, Pauli SA, Bohlen P, Sauer MV & Kitajewski J 2003 Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. Journal of Clinical Investigation 112 659-669. (doi:10.1172/JCI18740)